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Abstract
Background: Genetic variants within the major histocompatibility complex (MHC)
represent the strongest genetic susceptibility factors for primary sclerosing
cholangitis (PSC). Identifying the causal variants within this genetic complex
represents a major challenge due to strong linkage disequilibrium and an overall
high physical density of candidate variants. We aimed to refine the MHC
association in a geographically restricted PSC patient panel.
Methodology/Principal Findings: A total of 365 PSC cases and 368 healthy
controls of Scandinavian ancestry were included in the study. We incorporated data
from HLA typing (HLA-A, -B, -C, -DRB3, -DRB1, -DQB1) and single nucleotide
polymorphisms across the MHC (n518,644; genotyped and imputed) alongside
previously suggested PSC risk determinants in the MHC, i.e. amino acid variation
of DRb, a MICA microsatellite polymorphism and HLA-C and HLA-B according to
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their ligand properties for killer immunoglobulin-like receptors. Breakdowns of the
association signal by unconditional and conditional logistic regression analyses
demarcated multiple PSC associated MHC haplotypes, and for eight of these
classical HLA class I and II alleles represented the strongest association. A novel
independent risk locus was detected near NOTCH4 in the HLA class III region,
tagged by rs116212904 (odds ratio [95% confidence interval]52.32 [1.80, 3.00],
P51.35610211).
Conclusions/Significance: Our study shows that classical HLA class I and II
alleles, predominantly at HLA-B and HLA-DRB1, are the main risk factors for PSC
in the MHC. In addition, the present assessments demonstrated for the first time an
association near NOTCH4 in the HLA class III region.
Introduction
Primary sclerosing cholangitis (PSC) is a rare (prevalence 1/10,000) liver disease
resulting in chronic inflammation and concentric fibrosis of the intra- and extra
hepatic bile ducts. Medical therapy does not halt disease progression and up to
50% of the patients are in need of liver transplantation within 10–15 years of
diagnosis [1]. PSC is often associated with other immune-mediated diseases; most
frequently with inflammatory bowel disease (IBD). Co-occurrence of IBD shows
geographical variation, with highest frequencies of IBD occurring in Scandinavia
(approximately 80%) and lower frequencies in Southern Europe and Asia
(approximately 30–50%). Other immune-mediated comorbidities such as type 1
diabetes, autoimmune thyroid disorders, psoriasis and rheumatoid arthritis are
found in up to 25% of the patients [2] and shows a partially overlapping genetic
predisposition [3].
The presence of genetic components in PSC susceptibility is suggested by an
increased disease risk in siblings of PSC patients (9–39 fold). The statistically most
significant genetic associations are located within the major histocompatibility
complex (MHC) on chromosome 6p21. This genetic complex spans almost 4
million base pairs (Mbp), harboring approximately 260 genes. Many of these
genes have immune-related functions, the most important being the classical HLA
class I and II genes [4]. A strong genetic association within the MHC, as observed
in PSC, is a hallmark of most autoimmune and immune-mediated diseases. Due
to the complexity of the region, including extensive linkage disequilibrium (LD),
population heterogeneity and the high density of immune-related genes, it has for
most diseases been difficult to pinpoint the causal genetic variant(s) and hence the
functional implications of the genetic associations. Exceptions exist for which a
primary MHC risk factor has been identified, including HLA-DQ2 and -DQ8 in
celiac disease [5] and HLA-DQ*06:02 in narcolepsy [6]. Recent advances in single
nucleotide polymorphism (SNP) genotyping technologies with dense coverage in
the MHC and in silico imputation of missing SNP genotypes [7] as well as classical
MHC in PSC
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HLA alleles and their corresponding amino acid variants [8, 9], have facilitated
refinement of MHC associations in several diseases. This has proven most
successful for diseases with one prominent predisposing genetic factor mapping to
either the class I or II region, as observed in type 1 diabetes [10, 11], rheumatoid
arthritis [12] and multiple sclerosis [13]. For other MHC associated diseases, such
as PSC, the challenges associated with refinement of the association signal are
substantial, mainly due to the lack of a primarily associated locus, and the
presence of multiple conserved haplotypes [14–17].
Against this background, we aimed to refine the MHC associations in a
Scandinavian PSC population by exploring the extent of the various associated
haplotypes and to determine whether additional associations with non-classical
HLA genes could be detected. Two different approaches were applied. As no
primary HLA predisposition is known in PSC, we first set out to identify a
putative main susceptibility locus by unconditional multivariate logistic
regressions of data for six classical HLA class I and II genes (HLA-A, HLA-B, HLA-
C, DRB3, DRB1 and DQB1) obtained by direct sequencing. Next, HLA sequencing
data, more than 18,000 genotyped and imputed SNPs within the MHC and
information on previously reported associations with amino acid variation at
position 37 and 86 of the DRB1 locus [18], the MICA5.1 allele [19, 20] and HLA-B
and HLA-C killer immunoglobulin-like receptors (KIR) ligands (Bw4/Bw6 and
C1/C2, respectively) [19], were jointly considered in stepwise conditional logistic
regression models.
Materials and Methods
Study population
The study included 365 Scandinavian PSC patients recruited on admission to
Department of Transplantation Medicine, Oslo University Hospital,
Rikshospitalet, Oslo, Norway (n5232) and Department of Gastroenterology and
Hepatology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
(n5133). The diagnosis of PSC was based on generally accepted clinical,
biochemical, cholangiographic and histological criteria [1]. IBD was diagnosed
and classified according to standard endoscopic and histologic criteria and was
present in 86% of the patient population. A diagnosis of cholangiocarcinoma had
been made in 14% of the patients. Median age at diagnosis of PSC was 34 years
(range 12–75). An ethnically and gender-matched group (70% males) of healthy
controls (n5368) was randomly drawn from the Norwegian Bone Marrow Donor
Registry and anonymized after DNA retrieval. The registry comprises more than
25,000 individuals with a median age (range) of 38 (18–55) years. Our study was
restricted to the Scandinavian population to minimize the effect of population
ancestry and the variable degree of non-PSC immune-mediated co-morbidity on
MHC haplotype architecture.
MHC in PSC
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Written informed consent was obtained from all study participants. The study
was approved by The Regional Committee for Research Ethics in Southern
Norway and The Ethics Committee of Karolinska Institutet, Stockholm, Sweden.
HLA genotyping
For HLA class II, sequencing based HLA-DRB3 typing was performed using
previously described protocols [21], utilizing AssignSBT v3.2.7b for allele
assignment [22]. Four digit genotyping results were available for HLA-DRB1 and
HLA-DQB1 from a previous study that included the same patients and controls
[23]. For HLA class I, HLA-A, HLA-B and HLA-C genotypes were available from
another previous study that included the same patients and controls [19]. For
HLA-A and HLA-B, alleles were collated at serotype nomenclature level to reduce
the number of degrees of freedom in the logistic regression analysis and to ensure
comparability with the control data from the Norwegian Bone Marrow Donor
registry. Data on the MICA 5.1 variant as well as HLA-B and HLA-C KIR binding
epitopes (HLA-Bw4 and HLA-Bw6, HLA-C1 and HLA-C2, respectively) were also
available from other previous studies [19, 20].
MHC SNP genotyping and 1000G imputation
The SNPlex Genotyping System (Applied Biosystems) was used to genotype 471
SNPs spanning 16 MB (27.7–44.1 Mbp) covering the MHC (29,6–33,1 Mbp) [24].
The SNPs were selected based on published allele frequencies and genomic
location. Genotyping cluster-plots were manually inspected and poor performing
SNPs were excluded prior to further analyses. SNPs with low genotyping success
rate (,95%), minor allele frequency (MAF) ,1% and deviating from Hardy-
Weinberg equilibrium in controls (P-value ,161024), were excluded. A total of
405 SNPs passed quality control and served as input for imputation. Replication
genotyping of rs116212904 was performed using TaqMan technology (Applied
Biosystems).
For SNP imputation, we used the 1000 genomes reference data from individuals
of European ancestry (1000G Phase I v3 20101123, http://www.sph.umich.edu/
csg/abecasis/MACH/download/1000G.2012-03-14.html). This dataset consists of
758 phased haplotypes. Mach 1.0 was used to determine haplotypes based on the
genotyped SNPs [25], followed by genotype imputation using minmac v.
2012.5.29 [26, 27]. For downstream analyses only imputed SNPs with a
MAF .1% and r2 values above a MAF-specific r2 threshold were employed. To
determine the MAF-specific r2 threshold, the SNPs were split into three MAF
groups (1).1% and ,3%, 2).3% and ,5% and 3). 5%). The r2 threshold in
the respective groups was set so the average r2 was above 0.8. After applying these
criteria 18,644 SNPs (27.6–44.2 Mbp) were included in the statistical analyses.
The imputed dataset was converted to PLINK format using fcgene v.1.0.5,
subsequent LD analyses were done in Unphased v.3.0.10 and PLINK v.1.07 using
the imputed best-guess genotypes.
MHC in PSC
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Statistical analyses
Unconditional regressions including classical HLA class I and II alleles
One hypothesis is that the multiple associations previously reported in PSC are
caused by LD to primary associations to alleles at a single classical HLA locus. A
stepwise logistic regression approach [28] was used to test if allelic variation at one
of the six HLA loci; HLA-A, HLA-B, HLA-C, HLA-DRB3, HLA-DRB1 or HLA-
DQB1, could fully explain the HLA associations observed in PSC. The
contribution to the model of each of the loci were tested using a likelihood ratio
test, one at the time, comparing with a model containing each of the six loci as
baseline.
In PSC, no primary risk locus has been established. This complicates the
discrimination between potentially multiple, independent risk alleles in the MHC.
To determine which of the alleles, across HLA-A, HLA-B, HLA-C, HLA-DRB3,
HLA-DRB1 and HLA-DQB1, could best predict case-control status, the stepAIC
function in R (http://cran.r-project.org/web/packages/MASS/index.html) was
applied using all alleles at all six loci simultaneously. Due to strong LD between
DRB1 and DQB1 alleles in the Scandinavian population, these were combined and
assessed as DRB1-DQB1 haplotypes to reduce the degrees of freedom. The method
selects, at each step the covariate that, by exclusion or inclusion to the regression
model, decreases the Akaike Information Criterion (AIC) the most. To avoid
overfitting, we only kept the covariates that gave a significant contribution using
the likelihood ratio test and nominal significance threshold of P#0.01.
Conditional logistic regressions
Next, we wanted to comprehensively assess previously reported PSC associations
in the MHC together with classical HLA alleles and SNP data spanning the MHC,
in one model. To determine the relative impact of significant outcomes, stepwise
conditional logistic regressions were performed. Analyses were done in R v.3.0.1
with custom scripts (available from the authors on request). In total, 18,771
variables, consisting of the 18,644 SNPs, 95 HLA alleles (at HLA-A, HLA-B, HLA-
C, HLA-DRB3, HLA-DRB1 and HLA-DQB1), 20 DRB1-DQB1 haplotypes, amino
acid polymorphisms at position 37 (five) and 86 (two) of DRB1, the MICA5.1
allele and the four KIR epitopes, were individually tested for association in logistic
regression with a genetic additive model. To account for the uncertainty in
imputation, allele dosages from the imputation procedure represented the
different SNP genotypes. HLA alleles, DRB1-DQB1 haplotypes, amino acid
variants, the MICA5.1 allele and the KIR epitopes were converted into dosages for
each individual, i.e. 0, 1, or 2 copies. Amino acids at position 37 (Asparagine,
Leucine, Phenylalanine, Serine, Tyrosine) and 86 (Glycine, Valine) were assigned
by aligning DRB1 alleles in the IMGT/HLA database release 3.11.0. A study-
specific Bonferroni-corrected statistical significance threshold of P#2.66610-6
was set, according to the number of comparisons.
MHC in PSC
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Results
The MHC association in PSC can only be explained by multiple
independent variants
Many classical HLA genes and alleles have previously been reported to be
associated with PSC [29]. In an attempt to dissect a potential primary effect
within the MHC, either for classical HLA-loci or non-classical HLA loci, we
applied (i) unconditional multivariate regression models and (ii) conditional
univariate regressions.
Unconditional multivariate regressions result in independent HLA
class I and II associations
In the first strategy, we started by assessing whether the HLA associations in PSC
could be restricted to alleles at only one of the six classical HLA-loci genotyped
(i.e. HLA-A, HLA-B, HLA-C, DRB3, DRB1 and DQB1). This was not the case since
alleles at HLA-B, DRB1, DRB3 and DQB1 all provided statistically significant
contributions to the model over and above any of the other loci alone.
Secondly, we investigated which alleles at HLA-A, HLA-B, HLA-C and DRB3
(n546), and which DRB1-DQB1 haplotypes (n520), could represent primary
disease determinants by incorporating these 66 variants in regression modeling.
Several HLA alleles at different loci were significantly associated in the final model
(i.e. P#0.01) (Table 1). At HLA class I, HLA-B*08 (i.e. serotype B8) (OR [95%
CI]54.3 [3.0, 6.0]), -B*07 (i.e. serotype B7) (OR [95% CI]51.7 [1.2, 2.4]) and -
C*06 (OR [95% CI]52.5 [1.4, 4.5]) all conferred risk of PSC. B*08 and B*07 are
both representatives of conserved MHC haplotypes; i.e. the ancestral haplotype
8.1(AH8.1) and the ancestral haplotype 7.1 (AH7.1), respectively. Notably, the
DRB1 alleles found on these haplotypes, DRB1*03:01 (AH8.1) and DRB1*15:01
(AH7.1), did not show significant contributions over and above that exerted by
the HLA-B*08 and HLA-B*07 alleles, respectively. At HLA class II, there were
significant associations with both protective and risk DRB1-DQB1 haplotypes.
The DRB1*13:01–DQB1*06:03 (OR [95% CI)54.9 [3.1, 7.9]) association was the
strongest of the class II haplotypes, and the only class II haplotype conferring risk
in the final model. Three class II DRB1-DQB1 haplotypes; DRB1*04–DQB1*03
(OR [95% CI]50.4 [0.3, 0.6]), DRB1*07:01–DQB1*03:03 (OR [95% CI]50.1
[0.02, 0.6]) and 13:XX (i.e. all non-13:01 alleles)–DQB1*06 (OR [95% CI]50.3
[0.3, 0.6]), had a protective effect.
In summary, this first strategy was not able to identify one primary classical
HLA effect, but rather indicated that several HLA class I and II alleles are
independently associated with PSC. Furthermore, the analysis demonstrated the
presence of true protective effects as well as susceptibility effects, i.e. that the
DRB1*04, DRB1*07 and DRB1*13:02/DRB1*13:03 associations do not arise
because of the high frequencies of the risk alleles, but are independent from these
(Table 1 and S1 Table).
MHC in PSC
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Conditional analyses across the MHC confirm independent
associations with HLA class I and II alleles and detected a novel
independent association to an allele in the HLA class III region
In the second analytic strategy, we assessed the relative importance of several PSC-
associated polymorphisms with various biological implications, including SNPs,
alleles encoding classical HLA molecules and non-classical HLA molecules, ligands
for receptors located on natural killer cells and key amino acid variants possibly
influencing peptide presentation of the DRB1 molecule.
Fig. 1 shows the primary association results within the MHC, including all
tested variants. The statistically most significant association was found for DRb
amino acid position 37, i.e. Asparagine (OR [95% CI]53.30 [2.62, 4.17],
P51.11610222). The most significant association found for a HLA allele was with
DRB3*01:01 (OR [95% CI]53.51 [2.73, 4.51], P59.45610221), and the most
significant SNP association was with rs139345387 at 31.6 Mb (OR [95% CI]50.37
[0.29, 0.48], P56.85610217). Several HLA-DRB1 alleles in our population
encode Asparagine at position 37, including HLA-DRB1*03:01, *09:01, *13:01,
*13:02 and *14:02. Two of these alleles, DRB1*13:01 (P52.3061029), and *03:01
(P56.82610216), were significantly associated in the primary association analysis
(Fig. 1). The most strongly associated HLA-allele, HLA-DRB3*01:01, was found
on two PSC risk haplotypes; AH8.1 (i.e. A*01-B*08-C*07-DRB3*01:01-
DRB1*03:01-DQA1*05:01-DQB1*02:01) and DRB1*13:01-DQB1*06:03 in our
study population. DRB3*01:01 is however only in substantial LD with alleles on
the AH8.1 (r250.69 with DRB1*03:01 in controls) and not DRB1*13:01. This
means that DRB3 alleles other than DRB3*01:01 are observed together with
DRB1*13:01, and conversely, as evident from the AIC-based regressions in the
first analytic strategy, that DRB1*13:01 provides an effect over and above that
exerted by DRB3*01:01. The top 10 SNPs in the primary association analysis
(including rs139345387) were all part of the same LD-block and in considerable
Table 1. Unconditional, multivariate logistic regression modeling incorporating all detected alleles from sequencing-based classical HLA typing at six loci.
HLA alleles in final model OR (95% CI)
HLA class I loci:
HLA-B*08 4.3 (3.0–6.0)
HLA-B*07 1.7 (1.2–2.4)
HLA-C*06 2.5 (1.4–4.5)
DRB1-DQB1 blocks:
DRB1*13:01-DQB1*06:03 4.9 (3.1–7.9)
DRB1*04-DQB1*03 0.4 (0.3–0.6)
DRB1*07:01-DQB1*03:03 0.1 (0.02–0.6)
DRB1*13:XX-DQB1*06a 0.3 (0.3–0.6)
Significant contributions to disease status were established on the basis of a likelihood ratio test of the impact from each allele on the Akaike Information
Criterion (P#0.01). Due to the strong linkage disequilibrium (LD) between DRB1 and DQB1 alleles, and to reduce the degree of freedom of the test, they
were modeled as ‘‘DRB1-DQB1 blocks’’ according to LD. aDRB1*13:XX 5 all non-13:01 alleles, i.e. DRB1*13:02, 13:03 and 13:05.
CI: confidence interval, OR: odds ratio
doi:10.1371/journal.pone.0114486.t001
MHC in PSC
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LD with the AH8.1 alleles, most strongly with HLA-B*08 (r2 ranging from 0.43 to
0.83). Our peak SNP signal aligns with previous studies where the top SNP
associations were found in/or in the vicinity of HLA-B, tagging HLA-B*08
[3, 30, 31]. Given the different biological implications of the various poly-
morphisms included in this second strategy, one can argue in favor of various
subsequent conditional strategies in a follow-up of the primary association
analysis. Here we present three different strategies.
Fig. 1. Single marker association results for presently and previously implicated major histocompatibility complex (MHC) risk variants in primary
sclerosing cholangitis (PSC). The strength of association signal, -log10P-value (y-axis), is plotted against the position on chromosome 6 shown in million
base pairs (Mb, x-axis) for each of the 18,771 variables. The black, horizontal dotted line represents the Bonferroni-corrected statistical significance
threshold of P#2.6661026. Association results are categorized according to single nucleotide polymorphisms (SNPs), classical HLA alleles, DRB1-DQB1
haplotypes, previously reported amino acids, MICA5.1, as well as variants affecting HLA-B (i.e. Bw4 and Bw6) and HLA-C (i.e. C1 and C2) ligand abilities for
killer immunoglobulin-like receptors (KIR). The blue line shows recombination intensity (cM/Mb). Positions are given according to National Center for
Biotechnology Information’s build 37 (hg19).
doi:10.1371/journal.pone.0114486.g001
MHC in PSC
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Conditional analysis strategy I
We started with the AH8.1, and more specifically HLA-B*08, as the first
conditional variable. This allele was tagged through LD by the most significantly
associated SNP allele, and was also represented in the final model of the classical
HLA alleles assessed by global AIC (Table 1). After adjusting for the HLA-B*08
association, several statistically significant association signals remained in the
analysis (Fig. 2.Ia). The top signal was with components of the DRB1*13:01-
DQB1*06:03 haplotype, represented by the DRB1*13:01 allele (P52.25610213).
Adjusting for both the HLA-B*08 and HLA-DRB1*13:01 association resulted in
an association with Tyrosine at position 37 (Tyr37) of the DRb molecule
(P57.9961029) (Fig. 2.Ib). Tyr37 is in LD with the DRB1*04 and DRB1*11
alleles, both of which show reduced frequencies in PSC patients (S1 Table and S2d
Table in S2 Table). Non-associated alleles also exhibit Tyr37, notably, DRB1*08,
DRB1*10:01 and DRB1*13:03. Adjusting for the B*08, DRB1*13:01 and Tyr37
associations in the analysis resulted in a final, distinct residual signal in the class
III region (Fig. 2.Ic). The top SNP, rs116212904, achieved a significance level of
P51.35610211 in the primary association analysis, and P55.9461027 in this
final step of the first conditional analysis. This biallelic A/T SNP was one of the
405 genotyped SNPs that served as input for imputation. To validate the
association, we genotyped the same study population employing TaqMan
technology and obtained comparable frequencies of the A allele of 81% and 66%
in PSC and controls respectively (OR [95% CI)52.28 [1.79–2.91],
P51.67610211). rs116212904 (renamed to rs9267845) is part of a LD-block in
the class III region, located centromeric of the NOTCH4 gene. Notably, weak LD
was observed between this block and any of the PSC-associated HLA alleles,
DRB1-DQB1 haplotypes or amino acids tested in this study (illustrated in Fig. 2.Ic
and Fig. 3). This observation was supported by persistent association of all the
major risk and protective variants when correcting for the rs116212904
association (S1 Fig.). Concluding strategy I, when conditioning on all four
variables (i.e. B*08, DRB1*13:01, Tyr37 and rs116212904) in the regression
analysis, no residual associations were left within the MHC (Fig. 2.Id).
Conditional analysis strategy II
A second conditional approach was performed by selecting the most significant
HLA-allele; DRB3*01:01, as the primary conditioning variable, resulting in a top
peak at Tyr37. Since DRB3*01:01 is part of the AH8.1, the observed elimination of
the B*08 association (P-value dropping from 3.14610217 to 0.02) was expected
(Fig. 2.IIa). Although DRB3*01:01 is observed on some DRB1*13:01-DQB1*06:03
haplotypes, we would not expect this association signal to drop accordingly, due
to lack of LD. A marginal drop in P-value for DRB1*13:01 from 2.3061029 to
4.0361028 confirmed this prediction, indicating an independent association of
DRB1*13:01-DQB1*06:03, irrespective of DRB3*01:01 status. Further condition-
ing on both DRB3*01:01 and Tyr37 resulted in a significant residual association
signal within class III, peaking at rs116212904 (Fig. 2.IIb), the same SNP
identified in the first conditional strategy. Conditioning on DRB3*01:01, Tyr37
MHC in PSC
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Fig. 2. Conditional logistic regression analyses within the major histocompatibility complex (MHC) in primary sclerosing cholangitis (PSC). The
three various conditional strategies employed and their conditional steps are indicated by Ia-Id, IIa-IIc and IIIa-IIIc. For all panels the conditional P-values (y-
axis) are plotted against the position on chromosome 6 shown in million base pairs (Mb, x-axis). HLA alleles, DRB1-DQB1 haplotypes, SNPs, the MICA5.1
MHC in PSC
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and rs116212904 left no significant residual association signals within the MHC
(Fig. 2.IIc). However, a non-significant association (according to the study-
specific significance threshold) was observed with DRB1*13:01-DQB1*06:03
(P57.1161025 for DRB1*13:01), indicating the presence of residual effects
allele and KIR ligands are distinctly designated (see legend in panel Ia). The significance threshold (P#2.6661026) is indicated by the black, horizontal
dotted line.
doi:10.1371/journal.pone.0114486.g002
Fig. 3. The extension of nine significantly primary sclerosing cholangitis (PSC) associated major histocompatibility complex (MHC) haplotypes,
observed in the unconditional and conditional regression analyses combined. The extension of the haplotypes is determined by three categories of
linkage disequilibrium (r2.0.2 (green), r2.0.5 (purple) and r2.0.8 (black), respectively) between a single haplotype marker (listed in the figure box) and any
single nucleotide polymorphism (SNP) in the dataset. Haplotype 1; AH8.1 (A*01-C*07-B*08-DRB3*01:01-DRB1*03:01-DQA1*05:01-DQB1*02:01).
Haplotype 2; HLA-DRB1*13:01-DQB1*06:03. Haplotype 3; HLA-DRB1*04-DQB1*03:01. Haplotype 4; HLA-DRB1*04-DQB1*03:02. Haplotype 5; HLA-
DRB1*15:01-DQB1*06:02. Haplotype 6; HLA-B*07. Haplotype 7; HLA-DRB3*03:01-DRB1*13:02-DQB1*06:04. Haplotype 8, HLA-DRB1*07:01-
DQB1*03:03. Haplotype 9; an independent LD-block centromeric of NOTCH4 in class III, tagged by rs116212904. DRB1*15:01 is part of the DR2 serotype
group.
doi:10.1371/journal.pone.0114486.g003
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represented by this haplotype, and not corrected for in this second conditional
strategy.
Conditional analysis strategy III
In the third and final conditional approach, the most significant association in the
primary association analysis, Asparagine at position 37 (Asn37) of DRB1, was
selected as the first conditional variable. This resulted in significant residual
associations for one protective, i.e. DRB3*03:01-DRB1*13:02-DQB1*06:04, and
one risk haplotype, DRB1*15:01-DQB1*06:02 (Fig. 2.IIIa). In addition there was a
significant residual signal for Serine at position 37 of DRB1 (Ser37), an amino acid
encoded by several DRB1*01 alleles (01:01, 01:02, 01:03 and 01:07), in addition to
DRB1*15:02, DRB1*16:01 and the previously and presently implicated
DRB1*15:01 allele [16]. We detected the same distinct peak as observed in strategy
I in the class III region, represented by rs115746570 (P51.2361029). This SNP
was the ninth most significant SNP in the third step of the first conditional
strategy (Fig. 2.Ic) and LD implies that it represents the same association located
centromeric to NOTCH4 as detected in the first two conditional approaches. After
conditioning on Asn37 and DRB3*03:01, significant residual associations were
detected for Serine and Tyrosine at position 37, DRB1*15:01 and two further
SNPs (one centromeric of NOTCH4 and another located between BTNL2 and
HLADRA) (Fig. 2.IIIb). Conditioning on Asn37, HLA-DRB3*03:01 and Ser37,
resulted in no significant residual PSC association signal within the MHC
(Fig. 2.IIIc).
In summary, this second analytic strategy resulted in six associated HLA
haplotypes, three risk; i.e. AH8.1 (A*01-B*08-C*07-DRB3*01:01-DRB1*03:01-
DQA1*05:01-DQB1*02:01), DRB1*13:01-DQB1*06:03 and DRB1*15:01-
DQB1*06:02, and three protective; i.e. DRB1*04-DQB1*03:01, DRB1*04-
DQB1*03:02 and DRB3*03:01-DRB1*13:02-DQB1*06:04. In addition, a signifi-
cant and independent association was found in class III in the vicinity of
NOTCH4 tagged by rs116212904.
Fig. 3 shows the extension, as determined by LD with any SNP in the dataset, of
nine significantly associated haplotypes from the first and second analytic strategy
combined.
Discussion
By combining novel unconditional multivariate logistic regression analyses and
three conventional conditional logistic regression strategies, we were able to
carefully characterize the presence and relationship of independent class I, class II
and class III contributions to the MHC associations in a Scandinavian PSC
population at an unprecedented level. A previously unreported class III
association centromeric to NOTCH4 was evident regardless of the statistical
approach taken to assess the data.
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A new finding in our study is the independent association located in the class
III region. The top seven SNPs (P-value#2.6661026) span a 1634 bp long region
(32193220 to 32194854), incorporating a non-coding region centromeric of
NOTCH4. There are several possible functional interpretations of this association.
The notch signaling pathway has numerous biological functions during the
development of the central nervous system and vascular system, and also appears
to play a role in the differentiation of naı¨ve CD4+ T cells [32]. Several diseases
have reported associations either within or in the vicinity of NOTCH4, most
extensively schizophrenia [33]. The second most significant SNP (rs115991177) in
conditional strategy one and two has previously been found to be associated with
type 1 diabetes, [34] and is in perfect LD (r251) with our top SNP (rs116212904).
rs116212904 is located 1376 base pairs centromeric of NOTCH4. However, SNPs
from the 1000G EUR population in moderate LD (i.e. r2$0.2) with rs116212904
span a large region (,400 kb), from 32191457 to 32594039, and encompasses
several class III and class II genes. Hence, the identified class III association could
potentially tag causal variants in genes other than NOTCH4, including HLA-
DRB1. Yet, tagging of classical HLA alleles seems unlikely, as there was only weak
LD between rs116212904 and any of the sequenced HLA class I or II alleles in our
control population. Furthermore, selecting rs116212904 as the first conditional
variable left significant residual signals for all the associated HLA-alleles, DRB1-
DQB1 haplotypes and amino acid variants found in the primary association
analysis. Finally, rs116212904 was also highly significant with a P-value of
1.62610259 in the previously published PSC Immunochip study [3], although
fine-mapping efforts were not undertaken in that study.
The association results for classical HLA class I and II alleles and haplotypes
from the unconditional and conditional logistic regressions are consistent with
previous work in the MHC in PSC, yet significantly extend our knowledge
regarding several of the risk haplotypes. Importantly, the HLA-B*08 and -B*07
alleles that remained in the final model of the unconditional regressions are part
of haplotypes which are highly conserved in the general population, stretching
from class I to II, i.e. AH8.1(A*01-C*07-B*08-DRB3*01:01-DRB1*03:01-
DQA1*05:01-DQB1*02:01) and AH7.1(C*07-B*07-DRB1*15:01-DQA1*01:02-
DQB1*06:02) [14–16]. The class II alleles on these haplotypes were excluded in
the final model in the unconditional regression analyses, suggesting that the class I
alleles, i.e. HLA-B*08 and HLA-B*07, most likely represent the causal variants on
these haplotypes. The unconditional logistic regression analyses also revealed a
novel class I association with the HLA-C*06 allele. Interestingly, an association
with HLA-C*06 is also seen in psoriasis [35], replication of this finding is however
necessary.
Supporting evidence for HLA-B*08, or a variant at a nearby locus, being the
primary risk variant on AH8.1 in PSC is as follows; (i) the association of HLA-
B*08, and not DRB1*03:01, is observed in African American PSC patients [36], a
population with generally lower LD levels, and (ii) the localization of the peak
association signal in, or in the vicinity, of HLA-B in both of the genome-wide
association studies that have been conducted in PSC [30, 31], as well as in the
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recently published PSC Immunochip study [3]. With the exception of
DRB3*01:01, HLA-B*08 was also the most significantly associated allele of the
genotyped alleles on the AH8.1 in the primary association analysis of the
conditional analytic strategy. The DRB3*01:01 allele is also found on the same
haplotype as HLA-DRB1*13:01, a known risk variant in PSC [15, 16], and its
superior association is attributable to its presence on both the AH8.1 and
DRB1*13:01 haplotype. Still, DRB3*01:01 is not likely to be a common risk
denominator for these two haplotypes for at least two reasons. Firstly, similar
associations have been found for the DRB3*01:01-DRB1*13:01 and DRB3*02:01-
DRB1*13:01 haplotypes [16], as also suggested by the lack of LD between
DRB3*01:01 and DRB1*13:01 (r250.04 in our controls). Secondly, our analysis
showed that there are persistent residual associations for DRB1*13:01 and
DQB1*06:03 after conditioning on DRB3*01:01.
A primary role for HLA-B*07 on the AH7.1 is not as evident as for HLA-B*08
on the AH8.1. The class II DRB1*15:01-DQB1*06:02 haplotype showed
associations in one of the conditional analysis strategies (strategy III), analogous
to additional association signals previously observed with this class II haplotype
after removing primary PSC-associated haplotypes from the study populations
(i.e. AH8.1 and DRB1*13:01-DQB1*06:03 positive individuals) [16]. Taken
together with the strength of the amino acid associations, the possibility remains
that for AH8.1 and AH7.1, additional class II effects may exist.
The second most significant association with a HLA haplotype in both analytic
approaches was with the DRB1*13:01-DQB1*06:03 haplotype. Although this
association was largely confined to class II, as the extent of LD is low on this
haplotype, genes other than DRB1 and DQB1 may be causative. Still, the
association with the DRB1*13:01 allele was slightly stronger than that for the
DRB1*13:01-DQB1*06:03 haplotype and the DQB1*06:03 allele in the conditional
analytic strategy. Also, given the association with DRB1*13:01 in African
Americans, who have comparable frequencies of DQB1*05:01 and DQB1*06:03 in
conjunction with DRB1*13:01 [37], it may be speculated that DRB1 is the
causative locus on this class II haplotype.
The most consistent protective association with PSC has been with the
DRB1*04-DQB1*03 haplotype [14–16]. This was also evident in the current study
where the DRB1*04-DQB1*03 haplotype was associated in both the unconditional
and conditional analytic approach. DRB1*04:01, DQB1*03:01 and DQB1*03:02
all obtained the study-specific significance threshold in the primary association
analysis of the conditional analytic strategy, with DRB1*04:04 being borderline
significant. The most significant and consistent protective association was with the
DQB1*03:01 allele, which could be explained by its frequent co-occurrence with
both DRB1*04:01 and DRB1*11:01 in Caucasians. A protective association with
DRB1*11 has previously been reported in PSC [17]. However, in the present
analysis, additional protective effects, besides the DRB1*04-DQB1*03 haplotype,
could only be ascribed to the previously reported HLA-DRB1*07:01-
DQA1*02:01-DQB1*03:03 haplotype [15]. The protective effects of the DRB1*04
and DRB1*07 associated haplotypes in the unconditional analyses are particularly
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notable, since the regression model intrinsically corrects for frequency biases due
to high frequencies of other alleles (displacement effect). Hence, the negative
associations with these two haplotypes are likely to represent biological effects that
are truly protective against PSC.
This study does not attempt to map disease predisposition to particular amino
acid variants in proteins encoded by PSC-associated HLA alleles. Rather, the
present study incorporated previously implicated amino acid variants (position 37
and 86) in DRb [18], and aimed to explore the relationship between these and the
full MHC architecture in PSC by also incorporating other previously published
candidate loci/variants (e.g. the MICA5.1 allele). Asparagine, Tyrosine and Serine
at position 37 were all significantly associated in several conditional strategies, in
addition to Valine and Glycine at position 86, in accordance with previous results
[18]. In the third conditional strategy, two amino acids, Asparagine and Serine at
position 37, accounted for most of the association signal. Still, attributing most of
the MHC association in PSC to these two amino acids would be incorrect. First,
we have not directly compared this contribution to that of amino acid variants at
HLA loci other than DRB1. Additionally, both the present and previous analyses
provide considerable evidence of a strong class I contribution to the AH8.1
association in PSC, meaning that Asparagine at position 37 is unlikely to represent
the full explanation. Still, the significance of the amino acid variants at position 37
and 86 seems highly robust and could be an important explanation for the class II
associations in PSC.
Increases in study size and SNP density alone have only to some extent proven
beneficial in the detailed resolving of MHC associations [3]. The lack of a
conclusive resolution along with the strength of the statistical associations
suggests, that rather than a lack of statistical power per se, there is a need for yet
more refined analytical strategies. We therefore chose to explore the utility of
various statistical approaches in a population of uniform geographical origin and
for whom SNP mapping data as well as direct, sequencing-based HLA and MICA
microsatellite typing were available. Unconditional, multi-locus regressions of
HLA alleles have not previously been performed and did show the unquestionable
presence of independent class I and class II associations. Similar approaches are
likely to be useful in other MHC associated conditions for which a primary
association has not been established. Several different conditional regressions were
presented in full to highlight the impact of analytical strategy on the results,
illustrating that one should be cautious when concluding on ‘‘causal’’ loci within
the MHC based on statistical evidence alone. The discourse facilitated by the three
strategies as a whole nevertheless allowed for a relatively robust detection of the
novel HLA class III PSC risk locus as well as corroboration of findings from the
unconditional multivariate analysis. The most important limitation to our study,
as also apparent in all studies based on HLA imputation from SNP data (see S3
Table), is that only a subset of the class II genes has been fully typed. Complete
HLA class II sequencing in study populations of multiple ethnicities [38] is
needed to establish which HLA class II determinants may be primarily involved in
PSC. Technology is improving [39], and a major challenge for the International
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PSC study group (www.ipscsg.org) moving forward will be to expand its DNA
collection to involve non-Caucasian and admixed patient populations.
Conclusion
By application of multiple statistical strategies, we were able to comprehensively
characterize the genetic architecture of the MHC-associated susceptibility to PSC.
A new finding is the likely existence of a distinct HLA class III risk locus in the
vicinity of NOTCH4. Further, by using unconditional models in assessing the
MHC associated susceptibility, new information was obtained concerning which
HLA class I and II loci may be primarily involved. The identification of the
primary risk alleles at the HLA-B and -DRB1 loci should facilitate further work to
characterize which antigens may be causing the immune responses involved in
PSC development.
Supporting Information
S1 Fig. Association analyses within the major histocompatibility complex
(MHC) in primary sclerosing cholangitis (PSC) after conditioning on
rs116212904. The conditional P-values (y-axis) are plotted against the position on
chromosome 6 shown in million base pairs (Mb, x-axis). HLA alleles, DRB1-
DQB1 haplotypes, SNPs, the MICA5.1 allele and killer immunoglobulin-like
receptor ligand properties for HLA-B and HLA-C are designated by distinct
symbols and colors as shown in legend. The Bonferroni-corrected statistical
significance threshold (P#2.6661026) is indicated by the black, horizontal
dotted line.
doi:10.1371/journal.pone.0114486.s001 (TIF)
S1 Table. Genotype distributions for the negatively associated DRB1*04,
DRB1*11 and DRB1*07 alleles in patients with primary sclerosing cholangitis
(PSC) as compared to healthy controls.
doi:10.1371/journal.pone.0114486.s002 (DOCX)
S2 Table. HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3 and HLA-DQB1 allele
frequencies in patients with primary sclerosing cholangitis (n5365) and healthy
controls (n5368).
doi:10.1371/journal.pone.0114486.s003 (DOCX)
S3 Table. Coverage of HLA class II genes (designated by X) by current study and
two commonly employed single nucleotide polymorphism (SNP) based imputa-
tion algorithms; HLA*IMP2 and SNP2HLA.
doi:10.1371/journal.pone.0114486.s004 (DOCX)
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